HCV Screening and Linkage to Care among Hospitalized Patients in Georgia

4th Hepatitis C Technical Advisory Group (TAG) Meeting Science Symposium Nov 28-30, 2018

Muazzam Nasrullah, *MD, MPH, PhD* Division of Viral Hepatitis (DVH) Centers for Disease Control and Prevention






National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Division of Viral Hepatitis

Background



National HCV Screening among Selected Populations, Georgia, January 2015 – October 2018



National HCV Screening Programs

January, 2015-April, 2017

- Screening data not transmitted in a uniform, standardized format (e.g. excel spreadsheets, hard copies)
- Confidentiality posed challenge in harm reduction sites

May, 2017-present

- Separate screening database/registry established in May, 2017
- Compatible with other health management information system
- Historical data validated and imported into the registry

Ministerial Order N01-45/δ (July 17, 2017)

 Requires all HCV screening providers to submit their screening data within 72 hours after the test is performed

Inpatient HCV Screening Program

Information Systems provide opportunity to link screening data with treatment database through unique ID

Patients per month initiating treatment were decreasing

~30,000 patients admitted in hospitals every month

Government plan to implement HCV screening program among all inpatients

Inpatient HCV Screening Program

Government Decree N445 – September 16, 2016

- Medical facilities mandated to provide and report the results of anti-HCV testing for all hospitalized patients via rapid and/or enzyme assay method.
- Exclusion of inpatients:
 - Registered in HCV Elimination Program
 - Documentation of completed antiviral treatment
 - Documentation of a HCV positive anti-HCV and/or RNA within last 6 months

Two HCV-related fields added

- HCV screening done (yes/no)
- HCV screening result (positive/negative)

Program launched on November 1, 2016


Inpatient HCV Screening Program

Government Resolution 169 – November 27, 2017

 HCV Core-antigen (CoreAg) test approved as an alternative to PCR for confirmation of active HCV infection

Government Resolution 118 – March 7, 2018

 All hospitals started using reflex CoreAg test for confirmation free of charge to patients (for those screened positive)



Objectives

To describe inpatient HCV screening rates in Georgia

To estimate linkage to care rates among those screened positive as part of inpatient HCV screening program in Georgia

To compare individuals who were linked and those not linked to HCV care in Georgia

Methods



Screening data from November, 2016 – July, 2018

- E-health from November, 2016-May, 2017
- National Screening Registry (through linking with E-health) from June, 2017-February, 2018
- National screening registry (through direct data entry) from March, 2018-July, 2018

 Linkage of screening data to treatment data through October, 2018

Linkage to care

Definition 1 (Linked 1):

Individuals who were screened positive during hospitalization in healthcare setting and <u>subsequently</u> <u>received</u> <u>confirmatory testing</u> at one of the HCV care provider sites after hospital discharge.

Definition 2 (Linked 2):

Individuals who were screened positive during hospitalization in healthcare setting, confirmed with chronic infection by <u>reflex CoreAg testing</u>, and <u>subsequently</u> <u>initiated</u> <u>treatment</u> at one of the HCV care provider sites after hospital discharge.



Results



Number of Inpatients Screened and Anti-HCV+, November 2016 – July 2018

Total inpatients screened: 498,957

Anti-HCV+: 3.8%

□ Total adult (≥18) inpatients screened: 394,208

Anti-HCV+: 4.8%

Adult males inpatients screened: 164,031

Anti-HCV+: 7.8%


Adult females inpatients screened: 230,177

Anti-HCV+: 2.6%

Number of Adult Inpatients Screened for HCV and Anti-HCV+ from November 2016 – July 2018



Inpatients Screened for HCV and Percent Anti-HCV Positive by Age Group, November 2016 – July 2018



Inpatients Screened Multiple Times, November 2016 – July 2018

75,353 (19.1%) adults were screened >1 time in hospital settings (4.1% were anti-HCV+)


 3,763 patients had at least 1 positive and 1 negative screening test

2,718 patients screened positive multiple times


Inpatients Screened and Linkage to HCV Care



Inpatients Screened and Linkage to HCV Care




Inpatients Screened and Linkage to HCV Care




Inpatients Linked to Care, November 2016 – July 2018

	Definition 1: Received Confirmatory Test after Screening (Nov, 2016-July, 2018)			Definition 2: Initiated Treatment after Positive Reflex CoreAg Confirmatory Test (March, 2018-July, 2018)		
	Linked (n=5,971)	Not Linked (n=8,566)	P-value	Linked (n=327)	Not Linked (n=1,453)	P-value
Sex Male Female	3,919 (42.0) 2,052 (39.4)	5,417 (58.0) 3,149 (60.6)	.003	180 (15.4) 147 (24.1)	989 (84.6) 464 (75.9)	<.0001
Age Group 18 - 29 30 - 39 40 - 49 50 - 59 60 +	286 (38.2) 819 (43.0) 1,247 (45.7) 1,329 (44.3) 2,290 (37.2)	463 (61.8) 1,088 (57.1) 1,481 (54.3) 1,668 (55.7) 3,866 (62.8)	<.0001	10 (20.0) 39 (17.4) 79 (20.7) 77 (20.5) 122 (16.3)	40 (80.0) 185 (82.6) 303 (79.3) 299 (79.5) 626 (83.7)	.307
Region of Hospital Adjara Guria Imereti Kakheti Kvemo Kartli Mtskheta-Mtianeti Racha-Lechkhumi/Kvemo Svaneti Samegrelo-Zemo Svaneti Samtskhe-Javakheti Shida Kartli Tbilisi Missing	469 (45.4) 83 (43.5) 1,045 (39.6) 151 (47.0) 177 (46.2) 43 (35.3) 7 (77.8) 300 (48.5) 44 (38.6) 160 (49.7) 2,959 (39.7) 533 (40.0)	565 (54.6) 108 (56.5) 1,596 (60.4) 170 (53.0) 206 (53.8) 79 (64.8) 2 (22.2) 319 (51.5) 70 (61.4) 162 (50.3) 4,488 (60.3) 801 (60.0)	<.0001	$\begin{array}{c} 37 \ (19.7) \\ 8 \ (21.1) \\ 44 \ (13.3) \\ 7 \ (10.6) \\ 13 \ (21.3) \\ 1 \ (9.1) \\ 0 \\ 20 \ (13.2) \\ 3 \ (14.3) \\ 26 \ (36.1) \\ 168 \ (20.1) \\ 0 \end{array}$	151 (80.3) 30 (79.0) 288 (86.8) 59 (89.4) 48 (78.7) 10 (90.9) 5 (100.0) 132 (86.8) 18 (85.7) 46 (63.9) 666 (79.9) 0	.0006


Hospital Inpatient Screening and Linkage to Care, November 2016 – July 2018



Hospital Inpatient Screening and Linkage to Care, November 2016 – July 2018



Hospital Inpatient Screening and Linkage to Care, November 2016 – July 2018



Summary

Overall anti-HCV+ among inpatient adults is 5%

Age and sex distribution of individuals screened correlate with seroprevalence survey

Linkage to HCV care rates vary depending upon how "linkage" is defined

Linked and those not linked to care vary by regions

Limitations

Screening Registry

- Does not allow for collection of data regarding testing eligibility
- No information on patient refusal

No information available on type of rapid test used by the facilities

No information available on post HCV testing counselling
Post HCV counselling started August, 2018

Conclusions

Definition of "linkage to HCV care" needs to be standardized

How "linkage to HCV care" is defined has significant impact on correctly documenting program progress

Targeted screening (men aged 30-59) may be more efficient/effective

Importance of Information Systems that allow to estimate linkage to care rates

Need of innovative interventions to ensure initiation of treatment

Next steps

Analyze data of screening, anti-HCV+, and linkage to HCV care by facility to assess gaps, learn best practices, and devise corrective actions

Analyze data of other screening programs (e.g., HR, HIV) and linkage to HCV care and assess gaps


Decrease barriers to linkage (recent survey presented earlier)

Use data/findings of innovative screening and linkage to care pilot projects (presented earlier)



- EXTRA SLIDES-

Care Cascade among Hospital Patients Linked to Care – Definition 1 – through October 31, 2018



Care Cascade among Hospital Patients Linked to Care -**Definition 2** – through October 31, 2018 **HCV Confirmatory Testing** 327 **HCV** confirmed chronic infection 327 **Completed work-up and** 327 await case review Authorized to begin treatment 327 **Initiated HCV treatment** 327 **Completed treatment** 15

Tested for SVR 1 Cured 1

Eligible for SVR